Women's Health reports on a study presented this month at the European Academy of Dermatology and Venereology's 2026 Congress in Vienna, which found nail disorders among two-thirds of GLP-1 users surveyed. The reported problems were nails lifting away from the nail bed and nails changing color.

GLP-1 drugs, the appetite-regulating class that includes the medications widely prescribed for obesity and type 2 diabetes, already carry a growing list of reported side effects including hair loss and vision changes. Nails are the newest entry, and the researchers themselves call the work preliminary.

The numbers, with denominators

Researchers surveyed 575 people taking GLP-1s and 1,329 people with obesity and/or type 2 diabetes who had never taken them. Nearly 40 percent of the GLP-1 group reported nails lifting away from the bed, against about 10 percent in the comparison group, and 46 percent reported color changes against 17 percent.

Those gaps look dramatic until you read the next paragraph of the reporting, which is where the interesting part actually lives. Around half of the GLP-1 users said they had nail problems before starting the medication.

Why the signal gets weaker

Other conditions explained part of the difference between groups, according to dermatologist and study coauthor Bianca Maria Piraccini, MD, PhD, who names psoriasis and iron deficiency among them. After the researchers accounted for those factors, the associations held but weakened.

In a separate analysis limited to changes that reportedly began after treatment started, neither association was statistically significant. "This is an important signal that warrants further investigation, but it does not establish that GLP-1 medications cause nail detachment or discoloration," obesity medicine physician-scientist Fatima Cody Stanford, MD, told the magazine.

Limitations

The study relied on self-reported symptoms, and Piraccini acknowledges the room for error when patients are asked to recall when something started and tie it to a treatment. Stanford says a stronger design would have a dermatologist examine nails before treatment and follow participants over time.

Where this leaves GLP-1 users

Nobody in the piece claims to know the mechanism. Stanford notes that reduced appetite can make adequate protein and micronutrient intake harder, while nail specialist Dana Stern, MD, points out that lifting is not associated with weight loss or low calorie and protein intake, leaving a direct drug effect as an unexplained possibility.